Valorisation and Competitiveness Cluster - Institute for Cancer and Immunology (ICI)

Objectives

• Research and development of therapeutic targets, new drugs and biomarkers,
• Strengthening of public-private partnerships,
• Creation of start-ups.

Context

Cancer and immunology are recognized as a priority by industry and by the Eurobiomed biocluster, which brings together industrial and academic research within the framework of the FHU-Marseille Immunopôle, and recently by the Sud-Provence Alpes-Côte d'Azur Regional Council within the framework of the Cancer Plan. The teams of the Institute of Cancer Immunology (ICI) have a very strong activity in terms of valorization supported by the SATT-SE and Inserm Transfert (many patents have been filed, some of which have been licensed to an industrial partner), including the creation of companies (Immunothech, Innate Pharma, Qiagen, ImCheck Therapeutics, HalioDx, Trophos Inc.).

ICI teams have a long history of collaboration with the private sector and have demonstrated their ability to establish contracts with world-class industries in the field of cancer and immunology. Very active funded structured alliances have been concluded by these teams with major pharmaceutical companies as well as with private foundations thanks to the attractiveness of ICI's scientific and medical teams.

Finally, the teams of the research centres(CRCM, CIML, IBDM, TAGC, INP, C2VN) and hospitals(IPC and APHM) have a long tradition of dissemination to the general public and regularly organise conferences and visits for students, patient associations and charities.)